All Releases
 |
EnteroMedics Reports Fourth Quarter 2011 Financial Results
Jan 26, 2012
|
18.7 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 01/26/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months and full year ended December 31, 2011.
For the full year e...
|
|
EnteroMedics Announces Completion of Patient Enrollment and Device Implantation in the ReCharge Pivotal Trial for Obesity
Dec 28, 2011
|
14.9 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 12/28/11 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has completed enrollment and device implantation in the Company's ReCharge pivotal trial for obesity. A...
|
|
EnteroMedics Receives First Approval for the Active Implantable Medical Device Components of the Maestro System From Australian Therapeutic Goods Administration (TGA)
Dec 13, 2011
|
14.2 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 12/13/11 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic disease and other gastrointestinal disorders, today announced approval by the Australian Therapeutic Goods Administration (TGA) of the critical active implantable medical dev...
|
|
EnteroMedics to Present at the Canaccord Genuity Sixth Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference
Nov 29, 2011
|
13.1 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 11/29/11 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., President and Chief Executive Officer, is scheduled to present at the Canaccord Ge...
|
|
EnteroMedics to Present at the 23rd Annual Piper Jaffray Healthcare Conference
Nov 22, 2011
|
13.0 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 11/22/11 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., President and Chief Executive Officer, is scheduled to present at the 23rd Annual ...
|
|
EnteroMedics to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
Nov 7, 2011
|
13.0 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 11/07/11 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Gregory S. Lea, Senior Vice President and Chief Financial Officer, is scheduled to present at Lazard Capit...
|
|
EnteroMedics Reports Third Quarter 2011 Financial Results
Oct 20, 2011
|
16.5 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 10/20/11 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three and nine months ended September 30, 2011.
For the three months e...
|
|
EnteroMedics Announces Updated Data From VBLOC DM2 ENABLE Study and Caloric Intake Study Results to Be Presented at the 29th Annual Obesity Society Meeting
Oct 3, 2011
|
19.0 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 10/03/11 --
EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that twelve month Caloric Intake Study data and updated clinical results from the Company's VBLOC-DM2 ENABLE (...
|
|
EnteroMedics to Present at the Craig-Hallum 2nd Annual Alpha Select Conference
Sep 30, 2011
|
13.1 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 09/30/11 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Gregory S. Lea, Senior Vice President and Chief Financial Officer, is scheduled to present at the Craig-Ha...
|
|
EnteroMedics Announces Closing of $14.5 Million Public Offering of Common Stock and Warrants
Sep 28, 2011
|
14.5 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 09/28/11 --
EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the closing of its previously announced public offering of 8,800,000 shares of its common stock and warrants t...
|
|
EnteroMedics Announces Pricing of $14.5 Million Public Offering of Common Stock and Warrants
Sep 23, 2011
|
14.2 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 09/23/11 --
EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has priced an underwritten public offering of 8,800,000 shares of its common stock and warrants to pur...
|
|
EnteroMedics Announces Proposed Public Offering of Common Stock and Warrants
Sep 22, 2011
|
13.7 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 09/22/11 --
EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced its intention to offer, subject to market and other conditions, shares of its common stock and warrants to pur...
|
|
EnteroMedics Announces Presentation of Maestro(R) RC System Clinical Data at the XVI World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders
Sep 2, 2011
|
15.4 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 09/02/11 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, today announced that data from the Company's VBLOC-DM2 ENABLE (DM2) trial evaluating the Company's second generation Maestro R...
|
|
EnteroMedics to Present at the Canaccord Genuity Annual Growth Conference
Aug 1, 2011
|
13.1 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 08/01/11 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., Chief Executive Officer, is scheduled to present at the Canaccord Genuity Annual Growth Conference in ...
|
|
EnteroMedics Reports Second Quarter 2011 Financial Results
Jul 21, 2011
|
18.1 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 07/21/11 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced financial results for the three and six months ended June 30, 2011.
For the three months ended June 30, 2011, the Co...
|
|
EnteroMedics Announces First Implant in ReCharge Pivotal Trial for Obesity
May 18, 2011
|
14.8 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 05/18/11 --
EnteroMedics Inc., (NASDAQ: ETRM), the only developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that the first patient has been implanted in the Company's ReCharge pivotal trial for obesity. The ReCharge trial is a random...
|
|
EnteroMedics Reports First Quarter 2011 Financial Results
Apr 25, 2011
|
16.6 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 04/25/11 --
EnteroMedics Inc., (NASDAQ: ETRM), the
developer of medical devices using neuroblocking technology to treat
obesity and other gastrointestinal disorders, today announced financial
results for the three months ended March 31, 2011.
For the three months ended March 31, 2011, the...
|
|
EnteroMedics Receives CE Mark Certification for the Maestro RC System, Allowing Australian Regulatory Application to Move Forward
Mar 28, 2011
|
15.4 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 03/28/11 --
EnteroMedics Inc., (NASDAQ: ETRM), the sole developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that it has received CE Mark approval of its second generation Maestro® RC System for the treatment of obesity using VBL...
|
|
EnteroMedics to Participate in 3rd Annual Lazard Capital Markets Medical Technology Conference
Feb 14, 2011
|
12.1 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 02/14/11 --
EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that it will participate in the 3rd Annual Lazard Capital Markets Medical Technology Conference in Snowbird, Utah, to take place f...
|
|
EnteroMedics Reports Fourth Quarter and Full Year 2010 Financial Results
Jan 27, 2011
|
15.6 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 01/27/11 --
EnteroMedics Inc., (NASDAQ: ETRM), the
developer of medical devices using neuroblocking technology to treat
obesity and other gastrointestinal disorders, today announced financial
results for the three months and full year ended December 31, 2010.
For the full year 2010, the C...
|
|
|
